Decreased Ferroportin Promotes Myeloma Cell Growth and Osteoclast Differentiation

作者：Gu, Zhimin; Wang, He; Xia, Jiliang; Yang, Ye; Jin, Zhendong; Xu, Hongwei; Shi, Jumei; De Domenico, Ivana; Tricot, Guido; Zhan, Fenghuang^*

来源：Cancer Research, 2015, 75(11): 2211-2221.

DOI：10.1158/0008-5472.CAN-14-3804

• MULTIPLE-MYELOMA
• HEPCIDIN EXPRESSION
• IRON HOMEOSTASIS
• DRUG-RESISTANCE
• CANCER
• ACTIVATION
• STAT3
• INTERNALIZATION
• METABOLISM
• INDUCTION

Iron homeostasis is disrupted in multiple myeloma, a difficult-to-cure plasma cell malignancy with lytic bone lesions. Here, we systematically analyzed iron gene expression signature and demonstrated that mRNA expression of iron exporter ferroportin (FPN1) is significantly downregulated in myeloma cells and correlates negatively with clinic outcome. Restoring expression of FPN1 reduces intracellular liable iron pool, inhibits STAT3-MCL-1 signaling, and suppresses myeloma cells growth. Furthermore, we demonstrated that mRNA of FPN1 is also downregulated at the initial stages of osteoclast differentiation and suppresses myeloma cell-induced osteoclast differentiation through regulating iron regulator TFRC, NF-kappa B, and JNK pathways. Altogether, we demonstrated that down-regulation of FPN1 plays critical roles in promoting myeloma cell growth and bone resorption in multiple myeloma.

• 出版日期2015-6-1
• 单位同济大学